Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

Exclusion Criteria

• •1.Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer)
• •lung squamous carcinoma
• •Other active malignancies requiring treatment
• •History of malignancy
• •Have got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (4.0), alopecia NOT included
• •Abnormal coagulation (INR\>1.5 or PT\>ULN+4s or APTT \>1.5 ULN); Patients with any physical signs of bleeding diathesis or receiving thrombolysis and anticoagulation
• •take major surgical treatments or have serious trauma before grouping, or the impact of surgery or trauma has been eliminated for less than 14 days
• •Patients with active or unable to control serious infections
• •Patients with Grade II or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc male ≥ 450 ms, female ≥ 470 ms) ; Patients with grade III to IV cardiac insufficiency, or left ventricular ejection fraction (LVEF) \<50% (NYHA Classification)
• •Patients with non-healing wounds or fractures
• •with kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus).
• •get arterial/venous thrombosis within 12 months, such as cerebrovascular accidents (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism
• •Patients with cirrhosis, decompensated liver disease, or active hepatitis Have suffered from hemorrhagic disease or coagulation dysfunction
• •diagnosed with disease which will severely endanger the security of patients or influence the completion of this research